Nymox Pharmaceutical Corporation

What they do

Nymox is a Bahamas-incorporated biopharmaceutical company developing therapeutic products, primarily Fexapotide Triflutate (NX-1207), which requires regulatory approval for commercialization. The company has not generated any sales in recent years and relies on financing to support its clinical trials and operations. It operates through its subsidiary, Nymox Corporation, and its common stock is listed on the OTCQB.

Revenue drivers

• Fexapotide Triflutate (NX-1207) — Lead product candidate in development; no regulatory approval or commercial sales to date, so no revenue generated.

Recent performance

For fiscal year 2024, Nymox reported zero revenue and a net loss of $4.49 million, compared to a net loss of $8.84 million in 2023. Operating loss was $4.28 million, down from $8.35 million. Total assets were $653,752 at year-end 2024, and total equity was negative $6.78 million. Cash and cash equivalents were not disclosed, but the company has not generated sales in any of the last five fiscal years.

Strategy

Nymox's strategy centers on advancing Fexapotide Triflutate through clinical development to obtain regulatory approval for commercialization. The company is also exploring collaboration, strategic partnering, or divestiture opportunities to support its operations. Management focuses on securing adequate financing to fund clinical trials and ongoing operations, and on defending pending litigation. The company aims to eventually transition from a development-stage to a later-stage biotechnology firm.

Risks

• Regulatory approval risk — Fexapotide Triflutate may not receive required regulatory approvals; existing or future clinical trial results may not demonstrate sufficient safety and efficacy.
• No revenue and financing risk — The company has had no sales for five years and depends on obtaining suitable financing to support operations and clinical trials.
• Litigation risk — Nymox faces pending litigation and may not successfully defend against current or unforeseeable future legal challenges.
• Competition and obsolescence risk — Products in development may be rendered obsolete by competitors' technologies, and the company may fail to compete effectively in its markets.

Outlook

Management acknowledges forward-looking uncertainties, including the ability to identify collaboration or partnership opportunities and obtain financing. Near-term priorities are advancing clinical development and pursuing regulatory clearances for Nymox's products. The company does not expect to pay dividends in the near future.